Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.

Br J Cancer · 2011 · PMC3078596 · PMID 21407216

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

a trend towards significanceP =0.059so close (0.05 < p ≤ 0.1)

Figure 2C showed that TSP-1 decreased, if compared with d1, after 5 months of treatment (d155) with a trend towards significance ( P =0.059), whereas significantly increased at the time of progression if compared with d155 ( P =0.049).

also in 2,760 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.